|
Published by: Global Markets Direct
Published: May. 29, 2008 - 300 Pages
Table of Contents
- 1 Table Of Contents
- 1.1 List of Tables
- 1.2 List of Figures
- 2 Introduction
- 2.1 What Is This Report About?
- 2.2 Definitions
- 2.2.1 Drug delivery devices
- 2.2.1.1 Needle-free Injections
- 2.2.1.2 Inhalation Systems
- 2.2.1.3 Infusion Systems
- 3 Healthcare Sector Review
- 3.1 Healthcare Expenditure
- 3.2 Healthcare Infrastructure
- 3.3 Healthcare Policy
- 3.3.1 Health Insurance Act
- 3.3.2 Healthcare Allowance Act
- 3.3.3 The Exceptional Medical Expenses Act
- 4 Drug Delivery Devices in Netherlands
- 4.1 Drug Delivery Devices Overall Revenues (2000-2012)
- 4.2 Drug Delivery Devices Overall Volume (2000-2012)
- 4.3 Drug Delivery Devices Company Shares (2005-2006)
- 5 Inhalation Systems in Netherlands
- 5.1 Inhalation Systems Overall Revenues (2000-2012)
- 5.1.1 Metered Dose Inhaler Devices Overall Revenues (2000-2012)
- 5.1.2 Dry Powder Inhaler Devices Overall Revenues (2000-2012)
- 5.2 Inhalation Systems Overall Volume (2000-2012)
- 5.2.1 Metered Dose Inhaler Devices Overall Volume (2000-2012)
- 5.2.2 Dry Powder Inhaler Devices Overall Volume (2000-2012)
- 5.3 Inhalation Systems Average Price (2000-2012)
- 5.3.1 Metered Dose Inhaler Devices Average Price (2000-2012)
- 5.3.2 Dry Powder Inhaler Devices Average Price (2000-2012)
- 5.4 Inhalation Systems Distribution Share (2005-2006)
- 5.5 Inhalation Systems Company Share (2005-2006)
- 6 Infusion Systems in Netherlands
- 6.1 Infusion Systems Overall Revenues (2000-2012)
- 6.1.1 Infusion Disposable Sets Overall Revenue (2000-2012)
- 6.1.2 Syringe Pumps Overall Revenue (2000-2012)
- 6.1.3 Infusion Pumps Overall Revenues (2000-2012)
- 6.2 Infusion Systems Overall Volume (2000-2012)
- 6.2.1 Infusion Disposable Sets Overall Volume (2000-2012)
- 6.2.2 Syringe Pumps Overall Volume (2000-2012)
- 6.2.3 Infusion Pumps Overall Volume (2000-2012)
- 6.3 Infusion Systems Average Price (2000-2012)
- 6.3.1 Infusion Pumps Average Price (2000-2012)
- 6.3.2 Syringe Pumps Average Price (2000-2012)
- 6.3.3 Infusion Disposable Sets Average Price (2000-2012)
- 6.4 Infusion Systems Distribution Share (2005-2006)
- 6.5 Infusion Systems Company Share (2005-2006)
- 7 AstraZeneca PLC Company Profile
- 7.1 Company Overview
- 7.2 Business Overview
- 7.2.1 Products
- 7.2.2 History
- 7.3 Locations And Subsidiaries
- 7.4 Financial Deals Landscape
- 7.4.1 AstraZeneca Completes $6,900 Million Private Placement
- 7.4.2 AstraZeneca Acquires MedImmune
- 7.4.3 AstraZeneca Acquires Biologics Manufacturing Facility From DSM Biologics
- 7.4.4 AstraZeneca Acquires Arrow Therapeutics
- 7.4.5 AstraZeneca Signs An Agreement With Palatin Technologies
- 7.4.6 AstraZeneca Signs An Agreement With Bristol-Myers Squibb
- 7.4.7 AstraZeneca Signs An Agreement With Cubist Pharmaceuticals
- 7.4.8 AstraZeneca Signs An Agreement With Par Pharmaceutical
- 7.4.9 Schering Signs An Agreement With AstraZeneca
- 7.4.10 AstraZeneca Signs An Agreement With Pozen
- 7.4.11 AstraZeneca Signs An Agreement With Abbott
- 7.4.12 AstraZeneca To Sell Its U.S Anaesthetic and Analgesic Product Portfolio To Abraxis BioScience
- 7.4.13 AstraZeneca Acquires KuDOS Pharmaceuticals
- 7.4.14 AstraZeneca Acquires A Stake In Protherics
- 7.4.15 AstraZeneca Signs An Agreement With Targacept
- 7.4.16 AstraZeneca Signs An Agreement With AtheroGenics
- 7.4.17 AstraZeneca UK Signs An Agreement With Protherics
- 7.4.18 AstraZeneca Signs An Agreement With Bayer Schering Pharma Aktiengesellschaft
- 7.4.19 AstraZeneca Signs An Agreement With Astex Therapeutics
- 7.4.20 AstraZeneca Signs An Agreement With Avanir Pharmaceuticals
- 7.4.21 AstraZeneca And Royal Cosun Sells Joint Venture Advanta To Syngenta
- 7.4.22 AstraZeneca Completes Private Placement Of $750 million
- 7.4.23 AstraZeneca Prices EUR750 Million Private Placement
- 7.4.24 AstraZeneca Prices Sterling Bond GBP350 Million And Euro750 Million Eurobond Private Placement
- 7.5 Recent Developments
- 7.5.1 Feb 22, 2008: AstraZeneca To Appeal Judgment In Alabama Medical Pricing Case
- 7.5.2 Feb 18, 2008: AstraZeneca Appoints Non-Executive Director
- 7.5.3 Dec 12, 2007: AstraZeneca Files Patent Infringement Actions in Response to Crestor ANDAs
- 7.5.4 Sep 28, 2007: AstraZeneca Appoints New CFO
- 7.5.5 Jul 25, 2007: AstraZeneca Appoints New Board Member
- 7.5.6 Jun 06, 2007: AstraZeneca CFO Resigns
- 7.5.7 Feb 22, 2007: AstraZeneca To Invest $120 Miilion For R&D In Macclesfield Site
- 7.5.8 Jan 30, 2007: Philips And Leading Healthcare Companies Join For Major Research And Development
- 7.5.9 Jan 22, 2007: AstraZeneca Makes $100 Million Research Investment In Boston
- 8 3M Company Profile
- 8.1 Company Overview
- 8.2 Business Overview
- 8.2.1 Consumer and Office
- 8.2.1.1 Overview
- 8.2.1.2 Capital Expenditure
- 8.2.1.3 Market View
- 8.2.1.4 Key Strategies
- 8.2.2 Display and Graphics
- 8.2.2.1 Overview
- 8.2.2.2 Financials
- 8.2.2.3 Capital Expenditure
- 8.2.2.4 Market View
- 8.2.2.5 Key Strategies
- 8.2.3 Electro and Communications
- 8.2.3.1 Overview
- 8.2.3.2 Financials
- 8.2.3.3 Capital Expenditure
- 8.2.3.4 Market View
- 8.2.3.5 Key Strategies
- 8.2.4 Health Care
- 8.2.4.1 Overview
- 8.2.4.2 Financials
- 8.2.4.3 Capital Expenditure
- 8.2.4.4 Market View
- 8.2.4.5 Key Strategies
- 8.2.5 Industrial and Transportation
- 8.2.5.1 Overview
- 8.2.5.2 Financials
- 8.2.5.3 Capital Expenditure
- 8.2.5.4 Market View
- 8.2.5.5 Key Strategies
- 8.2.6 Safety, Security and Protection Services
- 8.2.6.1 Overview
- 8.2.6.2 Financials
- 8.2.6.3 Capital Expenditure
- 8.2.6.4 Market View
- 8.2.6.5 Key Strategies
- 8.2.7 Products
- 8.3 Value Chain Analysis
- 8.3.1 Manufacturing
- 8.3.1.1 In House Manufacturing
- 8.3.2 Product Development
- 8.3.2.1 Regulatory Approvals
- 8.3.2.2 Clinical Trials
- 8.3.2.3 Research and Development
- 8.3.3 Sales and Marketing
- 8.3.3.1 Partnerships and Alliances
- 8.3.3.2 Licensing Agreements
- 8.3.3.3 E-distribution
- 8.4 SWOT Analysis
- 8.4.1 3M Company Strengths
- 8.4.1.1 Strong performance of Industrial and Transportation segment
- 8.4.1.2 Focused research and development
- 8.4.1.3 Decentralized operations
- 3M Company Weaknesses
- 8.4.1.4 Increased operating costs in the U.S.
- 8.4.1.5 Personal care segment’s poor performance
- 3M Company Opportunities
- 8.4.1.6 Expanding global presence
- 8.4.1.7 The liquid crystal display
- 8.4.1.8 Enhancing brand portfolio
- 3M Company Threats
- 8.4.1.9 Foreign currency fluctuations
- 8.4.1.10 Increasing cost of raw materials
- 8.4.1.11 Trend for private labels
8.5 Revenue Analysis - 8.5.1 Revenue by Segment
- 8.5.2 Revenue by Geography
8.6 Financial and Operational Review - 8.6.1 Financial Statements
- 8.6.2 Financial Ratios
8.7 Locations And Subsidiaries 8.8 Financial Deals Landscape - 8.8.1 3M Canada Acquires Les Entreprises Solumed
- 8.8.2 3M Acquires Bondo
- 8.8.3 3M Acquires Lingualcare
- 8.8.4 3M Acquires Abzil Industria E Comercio
- 8.8.5 3M Acquires Neo Plast
- 8.8.6 3M Acquires Assets Of DMS Chile
- 8.8.7 3M Acquires Business Of Innovative Paper Technologies
- 8.8.8 3M Acquires Powell
- 8.8.9 Gen-Probe Signs An Agreement With 3M Company
- 8.8.10 3M Acquires Acolyte Biomedica
- 8.8.11 3M Acquires Sealed Air Corp.'S Interest In Polymask Corp.
- 8.8.12 3M Sells Its Pharmaceutical Business To Meda AB
- 8.8.13 3M Acquires SoftMed Systems
- 8.8.14 3M Sells its Pharmaceuticals Business to Graceway
- 8.8.15 Gen-Probe Signs An Agreement With 3M
- 8.8.16 3M Sells its Pharmaceutical Operations in the Asia Pacific Region to Ironbridge Capital and Archer Capital
- 8.8.17 3M Acquires Biotrace International
- 8.8.18 Ekahau Secures $16 Million In Additional Funding
- 8.8.19 3M Acquires Brontes Technologies
- 8.8.20 3M acquires Nylonge Corp
- 8.8.21 3M Signs An Agreement With ClozeX Medical
- 8.8.22 3M Acquires OMNII Oral Pharmaceuticals
- 8.8.23 3M Sells Pharmaceutical Operations In The United States To Graceway
- 8.8.24 3M Sells Pharmaceutical Business In Europe To Meda AB
- 8.8.25 3M Sells Pharmaceutical Operations In The Asia Pacific To Ironbridge and Archer Capital
- 8.8.26 3M Acquires Accuspray Application Technologies Inc.
- 8.8.27 3M to acquire Rochford Thompson Equipment
- 8.8.28 3M To Acquire Aearo Technologies From Permira
- 8.8.29 Permira To Sell Aearo Technologies To 3M
8.9 Recent Developments - 8.9.1 Mar 31, 2008: HighJump Software Introduces Survey Management Solution for Direct Store Delivery Businesses
- 8.9.2 Mar 24, 2008: Brazil's Companhia de Transmissao de Energia Eletrica Paulista Chooses 3M ACCR for Upgrade of Line Over Parana River in Sao Paulo State
- 8.9.3 Mar 19, 2008: 3M to Headquarter Optical Systems Business in Asia
- 8.9.4 Mar 19, 2008: 3M To Headquarter Optical Systems Business In North Asia
- 8.9.5 Feb 11, 2008: 3M Increases Dividend for the 50th Straight Year
- 8.9.6 Nov 12, 2007: 3M Declares Quarterly Dividend
- 8.9.7 Oct 24, 2007: 3M And Sanyo Settle Suit On Lithium Ion Battery
- 8.9.8 Aug 13, 2007: 3M Declares Quarterly Dividend
- 8.9.9 May 08, 2007: 3M Declares Quarterly Dividend
- 8.9.10 Apr 30, 2007: Gen-Probe And 3M Collaborate To Develop Rapid Molecular Tests
9 Baxter International Company Profile 9.1 Company Overview 9.2 Business Overview - 9.2.1 BioScience
- 9.2.1.1 Overview
- 9.2.1.2 Financials
- 9.2.1.3 Capital Expenditure
- 9.2.2 Medication Delivery
- 9.2.2.1 Overview
- 9.2.2.2 Financials
- 9.2.2.3 Capital Expenditure
- 9.2.3 Renal
- 9.2.3.1 Overview
- 9.2.3.2 Financials
- 9.2.3.3 Capital Expenditure
- 9.2.4 Products
- 9.2.5 History
9.3 Value Chain Analysis - 9.3.1 Manufacturing
- 9.3.1.1 In House Manufacturing
- 9.3.2 Product Development
- 9.3.2.1 Regulatory Approvals
- 9.3.2.2 Clinical Trials
- 9.3.2.3 Research and Development
- 9.3.3 Sales and Marketing
- 9.3.3.1 Partnerships and Alliances
9.4 SWOT Analysis - 9.4.1 Baxter International Inc. Strengths
- 9.4.1.1 Diversified geographic presence
- 9.4.1.2 Sturdy research and development activities
- 9.4.1.3 Strong financial performance
- 9.4.2 Baxter International Inc. Weaknesses
- 9.4.2.1 High levels of inventory
- 9.4.2.2 Decline in revenues of medication delivery
- 9.4.2.3 Reduced capital expenditure
- 9.4.3 Baxter International Inc. Opportunities
- 9.4.3.1 Co-developing alliances
- 9.4.3.2 Increasing End Stage Renal Disease patients
- 9.4.3.3 FDA approval
- 9.4.4 Baxter International Inc. Threats
- 9.4.4.1 Legal proceedings
- 9.4.4.2 Patent litigation
- 9.4.4.3 Stringent regulations
9.5 Revenue Analysis - 9.5.1 Revenue by Segment
- 9.5.2 Revenue by Geography
9.6 Financial and Operational Review - 9.6.1 Financial Statements
- 9.6.2 Financial Ratios
9.7 Locations And Subsidiaries 9.8 Financial Deals Landscape - 9.8.1 Baiyunshan And Baxter Form A Joint Venture In China
- 9.8.2 Baxter Signs Licensing Agreement With Intercytex And Spinal Restoration
- 9.8.3 Baxter Sells Transfusion Therapies Business to Texas Pacific and Maverick Capital
- 9.8.4 B. Braun Acquires Renal Therapy Business Of Baxter
- 9.8.5 Innovata signs a license agreement with Baxter International
- 9.8.6 Kuros Biosurgery Signs An Agreement With Baxter International
- 9.8.7 Gambro Signs An Agreement With Baxter
- 9.8.8 Baxter Healthcare And Gambro Enter Into An Agreement
- 9.8.9 Baxter and Cerus Enter Into Agreement With BioOne for Commercialization Of INTERCEPT Blood System
- 9.8.10 Baxter International And Kaketsuken Enter Into Agreement
- 9.8.11 Baxter To Acquire 40% Stake In Shanghai Baxter From Worldbest Treeful
9.9 Recent Developments - 9.9.1 Jan 24, 2008: Baxter Achieves Record Sales and Earnings for Full-Year 2007
- 9.9.2 Dec 18, 2007: Baxter Elects CFO
- 9.9.3 Nov 13, 2007: Baxter Declares Quarterly Dividend
- 9.9.4 Aug 01, 2007: Baxter Elects New Board Director
- 9.9.5 Jul 31, 2007: Baxter Announces Quarterly Dividend
- 9.9.6 Mar 13, 2007: Baxter Declares Additional Share Repurchase Authorization
- 9.9.7 Feb 13, 2007: Baxter Announces Quarterly Dividend
- 9.9.8 Nov 28, 2006: Baxter Announces Annual Dividend
- 9.9.9 Sep 14, 2006: Baxter Appoints President, Baxter Latin America
9.10 Baxter International Inc. Pipeline Products - 9.10.1 Next-Generation Home Hemodialysis Machine
- 9.10.1.1 Product Overview
- 9.10.1.2 Product Description
- 9.10.1.3 Product Status
- 9.10.1.4 Product Milestone
10 GlaxoSmithKline plc Company Profile 10.1 Company Overview 10.2 Business Overview - 10.2.1 Products
- 10.2.2 History
10.3 Locations And Subsidiaries 10.4 Financial Deals Landscape - 10.4.1 GlaxoSmithKline Acquires CNS
- 10.4.2 Bayer HealthCare Acquires Pritor Business From GlaxoSmithKline
- 10.4.3 CNS To Merge With GlaxoSmithKline
10.5 Recent Developments - 10.5.1 Mar 19, 2008: GSK charitable support valued at GBP282 million in 2007
- 10.5.2 Feb 07, 2008: Full-year results announcement 2007
- 10.5.3 Dec 19, 2007: GlaxoSmithKline And Santaris Enter Global R&D Alliance
- 10.5.4 Dec 10, 2007: GlaxoSmithKline And OncoMed Form Strategic Alliance To Develop Cancer Stem Cell Antibody Therapeutics
- 10.5.5 Dec 07, 2007: GlaxoSmithKline Announces Board And Management Changes
11 Novartis AG Company Profile 11.1 Company Overview 11.2 Business Overview - 11.2.1 Major Products and Services
11.3 Locations And Subsidiaries 11.4 Financial Deals Landscape - 11.4.1 Bayer Schering Pharma Acquires U.S. Biologics Manufacturing Facility From Novartis
- 11.4.2 Novartis To Acquire Majority Stake In Alcon From Nestle
- 11.4.3 Novartis to sell Medical Nutrition business unit to Nestlé
- 11.4.4 Nestlé to Acquire Novartis Medical Nutrition
- 11.4.5 Novartis to sell its division Gerber Products Company to Nestle
12 Regulation System 12.1 Medical Equipment Approval Process - 12.1.1 Classification of Medical Devices
- 12.1.2 Conformity Assessment Process
- 12.1.2.1 Class I devices
- 12.1.2.2 Class IIa devices
- 12.1.2.3 Class IIb devices
- 12.1.2.4 Class III devices
12.2 Post Market Surveillance (PMS) 13 Pricing and Reimbursement 13.1 Pricing and Reimbursement in Netherlands 14 Distribution Structure 14.1 Distribution Structure in Netherlands 15 Appendix 15.1 Global Markets Direct Research Methodology 15.2 Coverage 15.3 Secondary Research 15.4 Primary Research 15.5 Models 15.6 Forecasts 15.7 Expert Panels 15.8 Currency Conversion 15.9 Contact Us 15.10 Disclaimer 1.1 List of TablesTable 1: Doctors by Specialty in Netherlands, 2000-2006 Table 2: Hospital Wards by Type in Netherlands, 2000-2006 Table 3: Drug Delivery Devices, Netherlands, Overall Revenues ($ mn), 2000-2012 Table 4: Drug Delivery Devices, Netherlands, Overall Revenues ($ mn), Historic, 2000-2007 Table 5: Drug Delivery Devices, Netherlands, Overall Revenues ($ mn), Forecast, 2007-2012 Table 6: Drug Delivery Devices, Netherlands, Category Revenues ($ mn), 2000-2012 Table 7: Drug Delivery Devices, Netherlands, Category Revenues ($ mn), Historic, 2000-2007 Table 8: Drug Delivery Devices, Netherlands, Category Revenues ($ mn), Forecast, 2007-2012 Table 9: Drug Delivery Devices, Netherlands, Category Volume (Units), 2000-2012 Table 10: Drug Delivery Devices, Netherlands, Category Volume (Units), Historic, 2000-2007 Table 11: Drug Delivery Devices, Netherlands, Category Volume (Units), Forecast, 2007-2012 Table 12: Drug Delivery Devices, Netherlands, Company Share by Revenue ($ mn), 2005-2006 Table 13: Inhalation Systems, Netherlands, Overall Revenues ($ mn), Historic, 2000-2007 Table 14: Inhalation Systems, Netherlands, Overall Revenues ($ mn), Forecast, 2007-2012 Table 15: Inhalation Systems, Netherlands, Revenue by Segment ($ mn), Historic, 2000-2007 Table 16: Inhalation Systems, Netherlands, Revenue by Segment ($ mn), Forecast, 2007-2012 Table 17: Metered Dose Inhaler Devices, Netherlands, Overall Revenues ($ mn), Historic, 2000-2007 Table 18: Metered Dose Inhaler Devices, Netherlands, Overall Revenues ($ mn), Forecast, 2007-2012 Table 19: Dry Powder Inhaler Devices, Netherlands, Overall Revenues ($ mn), Historic, 2000-2007 Table 20: Dry Powder Inhaler Devices, Netherlands, Overall Revenues ($ mn), Forecast, 2007-2012 Table 21: Inhalation Systems, Netherlands, Overall Volume (Units), Historic, 2000-2007 Table 22: Inhalation Systems, Netherlands, Overall Volume (Units), Forecast, 2007-2012 Table 23: Metered Dose Inhaler Devices, Netherlands, Overall Volume (Units), Historic, 2000-2007 Table 24: Metered Dose Inhaler Devices, Netherlands, Overall Volume (Units), Forecast, 2007-2012 Table 25: Dry Powder Inhaler Devices, Netherlands, Overall Volume (Units), Historic, 2000-2007 Table 26: Dry Powder Inhaler Devices, Netherlands, Overall Volume (Units), Forecast, 2007-2012 Table 27: Metered Dose Inhaler Devices, Netherlands, Average Price ($), Historic, 2000-2007 Table 28: Metered Dose Inhaler Devices, Netherlands, Average Price ($), Forecast, 2007-2012 Table 29: Dry Powder Inhaler Devices, Netherlands, Average Price ($), Historic, 2000-2007 Table 30: Dry Powder Inhaler Devices, Netherlands, Average Price ($), Forecast, 2007-2012 Table 31: Inhalation Systems, Netherlands, Distribution Share by Revenue ($ mn), 2005-2006 Table 32: Inhalation Systems, Netherlands, Company Share by Revenue ($ mn), 2005-2006 Table 33: Infusion Systems, Netherlands, Overall Revenues ($ mn), Historic, 2000-2007 Table 34: Infusion Systems, Netherlands, Overall Revenues ($ mn), Forecast, 2007-2012 Table 35: Infusion Systems, Netherlands, Revenue by Segment ($ mn), Historic, 2000-2007 Table 36: Infusion Systems, Netherlands, Revenue by Segment ($ mn), Forecast, 2007-2012 Table 37: Infusion Disposable Sets, Netherlands, Overall Revenues ($ mn), Historic, 2000-2007 Table 38: Infusion Disposable Sets, Netherlands, Overall Revenues ($ mn), Forecast, 2007-2012 Table 39: Syringe Pumps, Netherlands, Overall Revenues ($ mn), Historic, 2000-2007 Table 40: Syringe Pumps, Netherlands, Overall Revenues ($ mn), Forecast, 2007-2012 Table 41: Infusion Pumps, Netherlands, Overall Revenues ($ mn), Historic, 2000-2007 Table 42: Infusion Pumps, Netherlands, Overall Revenues ($ mn), Forecast, 2007-2012 Table 43: Infusion Systems, Netherlands, Overall Volume (Units), Historic, 2000-2007 Table 44: Infusion Systems, Netherlands, Overall Volume (Units), Forecast, 2007-2012 Table 45: Infusion Disposable Sets, Netherlands, Overall Volume (Units), Historic, 2000-2007 Table 46: Infusion Disposable Sets, Netherlands, Overall Volume (Units), Forecast, 2007-2012 Table 47: Syringe Pumps, Netherlands, Overall Volume (Units), Historic, 2000-2007 Table 48: Syringe Pumps, Netherlands, Overall Volume (Units), Forecast, 2007-2012 Table 49: Infusion Pumps, Netherlands, Overall Volume (Units), Historic, 2000-2007 Table 50: Infusion Pumps, Netherlands, Overall Volume (Units), Forecast, 2007-2012 Table 51: Infusion Pumps, Netherlands, Average Price ($), Historic, 2000-2007 Table 52: Infusion Pumps, Netherlands, Average Price ($), Forecast, 2007-2012 Table 53: Syringe Pumps, Netherlands, Average Price ($), Historic, 2000-2007 Table 54: Syringe Pumps, Netherlands, Average Price ($), Forecast, 2007-2012 Table 55: Infusion Disposable Sets, Netherlands, Average Price ($), Historic, 2000-2007 Table 56: Infusion Disposable Sets, Netherlands, Average Price ($), Forecast, 2007-2012 Table 57: Infusion Systems, Netherlands, Distribution Share by Revenue ($ mn), 2005-2006 Table 58: Infusion Systems, Netherlands, Company Share by Revenue ($ mn), 2005-2006 Table 59: AstraZeneca PLC, Subsidiaries Table 59: AstraZeneca PLC, Subsidiaries(Contd..) Table 60: 3M Company, SWOT Analysis, 2006 Table 61: 3M Company, Revenue by Segment, USD Million, 2003-2007 Table 62: 3M Company, Revenue by Geography, USD Million, 2003-2007 Table 63: 3M Company, Financial Statements, USD Million, 2003-2007 Table 64: 3M Company, Financial Ratios, USD Million, 2003-2007 Table 65: 3M Company, Subsidiaries Table 66: Baxter International Inc., SWOT Analysis, 2006 Table 67: Baxter International Inc., Revenue by Segment, USD Million, 2003-2007 Table 68: Baxter International Inc., Revenue by Geography, USD Million, 2003-2007 Table 69: Baxter International Inc., Financial Statements, USD Million, 2003-2007 Table 70: Baxter International Inc., Financial Ratios, USD Million, 2003-2007 Table 71: Baxter International Inc., Other Locations Table 72: Baxter International Inc., Subsidiaries Table 73: GlaxoSmithKline plc, Subsidiaries Table 73: GlaxoSmithKline plc, Subsidiaries(Contd..) Table 74: Novartis Medical Nutrition, Other Locations Table 74: Novartis Medical Nutrition, Other Locations(contd..) Table 75: Currency Conversion from USD to Local Currency at 2007 Constant Rate 1.2 List of FiguresFigure 1: Total Healthcare Expenditure in Netherlands, 2000 - 2006 Figure 2: Healthcare Financing Framework in Netherlands, 2005 Figure 3: Drug Delivery Devices, Netherlands, Overall Revenues ($ mn), 2000-2012 Figure 4: Drug Delivery Devices, Netherlands, Overall Revenues ($ mn), Historic, 2000-2007 Figure 5: Drug Delivery Devices, Netherlands, Overall Revenues ($ mn), Forecast, 2007-2012 Figure 6: Drug Delivery Devices, Netherlands, Category Revenues ($ mn), 2000-2012 Figure 7: Drug Delivery Devices, Netherlands, Category Revenues ($ mn), Historic, 2000-2007 Figure 8: Drug Delivery Devices, Netherlands, Category Revenues ($ mn), Forecast, 2007-2012 Figure 9: Drug Delivery Devices, Netherlands, Category Volume (Units), 2000-2012 Figure 10: Drug Delivery Devices, Netherlands, Category Volume (Units), Historic, 2000-2007 Figure 11: Drug Delivery Devices, Netherlands, Category Volume (Units), Forecast, 2007-2012 Figure 12: Drug Delivery Devices, Netherlands, Company Share (%), 2006 Figure 13: Inhalation Systems, Netherlands, Overall Revenues ($ mn), Historic, 2000-2007 Figure 14: Inhalation Systems, Netherlands, Overall Revenues ($ mn), Forecast, 2007-2012 Figure 15: Inhalation Systems, Netherlands, Revenue by Segment ($ mn), Historic, 2000-2007 Figure 16: Inhalation Systems, Netherlands, Revenue by Segment ($ mn), Forecast, 2007-2012 Figure 17: Metered Dose Inhaler Devices, Netherlands, Overall Revenues ($ mn), Historic, 2000-2007 Figure 18: Metered Dose Inhaler Devices, Netherlands, Overall Revenues ($ mn), Forecast, 2007-2012 Figure 19: Dry Powder Inhaler Devices, Netherlands, Overall Revenues ($ mn), Historic, 2000-2007 Figure 20: Dry Powder Inhaler Devices, Netherlands, Overall Revenues ($ mn), Forecast, 2007-2012 Figure 21: Inhalation Systems, Netherlands, Overall Volume (Units), Historic, 2000-2007 Figure 22: Inhalation Systems, Netherlands, Overall Volume (Units), Forecast, 2007-2012 Figure 23: Metered Dose Inhaler Devices, Netherlands, Overall Volume (Units), Historic, 2000-2007 Figure 24: Metered Dose Inhaler Devices, Netherlands, Overall Volume (Units), Forecast, 2007-2012 Figure 25: Dry Powder Inhaler Devices, Netherlands, Overall Volume (Units), Historic, 2000-2007 Figure 26: Dry Powder Inhaler Devices, Netherlands, Overall Volume (Units), Forecast, 2007-2012 Figure 27: Metered Dose Inhaler Devices, Netherlands, Average Price ($), Historic, 2000-2007 Figure 28: Metered Dose Inhaler Devices, Netherlands, Average Price ($), Forecast, 2007-2012 Figure 29: Dry Powder Inhaler Devices, Netherlands, Average Price ($), Historic, 2000-2007 Figure 30: Dry Powder Inhaler Devices, Netherlands, Average Price ($), Forecast, 2007-2012 Figure 31: Inhalation Systems, Netherlands, Distribution Share (%), 2006 Figure 32: Inhalation Systems, Netherlands, Company Share (%), 2006 Figure 33: Infusion Systems, Netherlands, Overall Revenues ($ mn), Historic, 2000-2007 Figure 34: Infusion Systems, Netherlands, Overall Revenues ($ mn), Forecast, 2007-2012 Figure 35: Infusion Systems, Netherlands, Revenue by Segment ($ mn), Historic, 2000-2007 Figure 36: Infusion Systems, Netherlands, Revenue by Segment ($ mn), Forecast, 2007-2012 Figure 37: Infusion Disposable Sets, Netherlands, Overall Revenues ($ mn), Historic, 2000-2007 Figure 38: Infusion Disposable Sets, Netherlands, Overall Revenues ($ mn), Forecast, 2007-2012 Figure 39: Syringe Pumps, Netherlands, Overall Revenues ($ mn), Historic, 2000-2007 Figure 40: Syringe Pumps, Netherlands, Overall Revenues ($ mn), Forecast, 2007-2012 Figure 41: Infusion Pumps, Netherlands, Overall Revenues ($ mn), Historic, 2000-2007 Figure 42: Infusion Pumps, Netherlands, Overall Revenues ($ mn), Forecast, 2007-2012 Figure 43: Infusion Disposable Sets, Netherlands, Overall Volume (Units), Historic, 2000-2007 Figure 44: Infusion Disposable Sets, Netherlands, Overall Volume (Units), Forecast, 2007-2012 Figure 45: Syringe Pumps, Netherlands, Overall Volume (Units), Historic, 2000-2007 Figure 46: Syringe Pumps, Netherlands, Overall Volume (Units), Forecast, 2007-2012 Figure 47: Infusion Pumps, Netherlands, Overall Volume (Units), Historic, 2000-2007 Figure 48: Infusion Pumps, Netherlands, Overall Volume (Units), Forecast, 2007-2012 Figure 49: Infusion Pumps, Netherlands, Average Price ($), Historic, 2000-2007 Figure 50: Infusion Pumps, Netherlands, Average Price ($), Forecast, 2007-2012 Figure 51: Syringe Pumps, Netherlands, Average Price ($), Historic, 2000-2007 Figure 52: Syringe Pumps, Netherlands, Average Price ($), Forecast, 2007-2012 Figure 53: Infusion Disposable Sets, Netherlands, Average Price ($), Historic, 2000-2007 Figure 54: Infusion Disposable Sets, Netherlands, Average Price ($), Forecast, 2007-2012 Figure 55: Infusion Systems, Netherlands, Distribution Share (%), 2006 Figure 56: Infusion Systems, Netherlands, Company Share (%), 2006 Figure 57: 3M Company, Value Chain Analysis Figure 58: Baxter International Inc., Value Chain Analysis Figure 59: Flowchart for Classification of Non-invasive Devices in Netherlands, 2007 Figure 60: Flowchart for Classification of Invasive Devices in Netherlands, 2007 Figure 61: Flowchart for Classification of Invasive Devices in Netherlands, 2007 Figure 62: Flowchart for Classification of Invasive Devices in Netherlands, 2007 Figure 63: Flowchart for Classification of Invasive Devices in Netherlands, 2007 Figure 64: Flowchart for Classification of Active Devices in Netherlands, 2007 Figure 65: Flowchart for Classification of Active Devices in Netherlands, 2007 Figure 66: Flowchart for Classification of Devices except Non-invasive, Invasive and Active Devices in Netherlands, 2007 Figure 67: Conformity Assessment of Class-I Medical Devices in Netherlands, 2007 Figure 68: Conformity Assessment of Class-IIa Medical Devices in Netherlands, 2007 Figure 69: Conformity Assessment of Class-IIb Medical Devices in Netherlands, 2007 Figure 70: Conformity Assessment of Class-III Medical Devices in Netherlands, 2007 Figure 71: Global Markets Direct Methodology
AbstractSummary
This report is an essential source for in-depth information and data relating to the Netherlands Drug Delivery Devices devices market. It also offers detailed and comprehensive coverage of market revenue, volume, distribution and company share information; and latest news, financial deals and pipeline products information of each of the key sub-segments of the Drug Delivery Devices in Netherlands
Scope- The report provides drug delivery devices information broken down into detailed categories and segments in Netherlands.
- Total revenues, products sold, end users, and average pricing.
- Market shares of all the key competitors.
- Key pipeline products that are set to shape the market, broken down by sector.
- Information on the top medical equipment companies in the sector in the country covering business description, strategic analysis, and financial information.
- Healthcare structure, regulatory environment, approval process, pricing trends and reimbursement.
- Product and brand updates, strategy changes, R&D projects, corporate expansions and contractions and regulatory changes.
- Key mergers and acquisitions, partnerships, private equity investments and IPOs.
- Customer, hospitals and physicians data.
Reasons to buy- Gain a strong understanding of the drug delivery devices market in Netherlands.
- Evaluate and compare the attractiveness of the market in the country.
- Identify growth segments and opportunities in each industry sector within the country.
- Evaluate the pipeline of key products that will change the sector, and identify threats and opportunities before the products are launched in the country.
- Analyze the competitiveness of the market in the country and identify hotspots.
- Develop strategies based on the latest product, brand, expansion and research and development news in the country.
- Do deals with an understanding of how competitors are financed, and the mergers and partnerships that have shaped the market in the country.
- Identify and analyze the strengths and weaknesses of the industry incumbents in the country.
Get Full Details About This Report >>
|
|
US: 800.298.5699
Int'l: +1.240.747.3093
|
|
|
